Marti Technologies (MRT) Announces Amendment to Extend its Share Repurchase Program

Türkiye’s leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced an amendment to extend its share repurchase program.

The Company’s Board of Directors (the “Board”) authorized a six month extension to its share repurchase program under which the Company may repurchase up to $2.5 million of its outstanding Class A ordinary shares until October 9, 2025. The share repurchase program was originally initiated on January 10, 2024 and was previously amended to extend the term until April 9, 2025. In addition, the Board amended the ceiling price from $5.00 per share to up to $6.00 per share for the share repurchases. As of market close on March 21, 2025, the Company's share price was $2.87.

The amended repurchase program is effective immediately and is valid until October 9, 2025 (the “Repurchase Program”). Under the Repurchase Program, the Company may repurchase Class A ordinary shares in privately negotiated or open-market transactions in accordance with applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The Board may periodically review the Company’s Repurchase Program and decide to extend its terms or increase the authorized amount. The Repurchase Program may also be suspended or discontinued by the Board at any time.

The specific timing and amount of repurchases will be at the discretion of the Company’s management team, and will depend on a variety of factors, including its assessment of the intrinsic value of the Company’s Class A ordinary shares, the market price of the Company’s Class A ordinary shares, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal, regulatory and contractual restrictions and the Company’s capital and business strategy.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Comfort Systems USA names new COO and Chief Strategy Officer
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval